Search
Taspoglutide
go.drugbank.com/drugs/DB14027InvestigationalAs of May 2013 no new trials had been registered. … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
Salicylamide
go.drugbank.com/drugs/DB08797ApprovedSalicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties.
EGT-101
go.drugbank.com/drugs/DB17645ExperimentalDeveloped by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919] … EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.
Novaferon
go.drugbank.com/drugs/DB16483InvestigationalCategories: Experimental Unapproved Treatments for COVID-19Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.
AEG35156
go.drugbank.com/drugs/DB06184InvestigationalXIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis. … AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors.
Ohmefentanyl
go.drugbank.com/drugs/DB01570ExperimentalIllicitOhmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are used for tranquilizing large animals such as elephants … Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine.
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Cilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCompared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMetrizamide
go.drugbank.com/drugs/DB01578ExperimentalMetrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity.